E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with mild to moderate seborrheic dermatitis of the facial area and meeting the specific eligibility criteria |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012488 |
E.1.2 | Term | Dermatitis seborrheic |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this double-blind, randomized, controlled, multicenter, parallel-group phase III pilot-study is to show a superiority of AzA 15% gel SH H 655BA over its vehicle („placebo“; SH H 655PBA) in the treatment of patients with mild to moderate seborrheic dermatitis. The study is of explorative nature, the potential efficacy of the AzA 15% gel in seborrheic dermatitis is not known. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
|
E.3 | Principal inclusion criteria |
Patients who meet all of the following inclusion criteria are eligible for this study:
1. Written informed consent (signed and dated) 2. Willingness and capability to follow all study procedures 3. Male or female patients with a minimum age of 18 years 4. Stable or exacerbating seborrheic dermatis of the face area 5. Investigator’s Global Assessment score at baseline of 2 to 4 (4 IGA 2)
|
|
E.4 | Principal exclusion criteria |
Patients who meet any of the following exclusion criteria are not eligible for this study and are not to be randomized:
1. Pregnancy at baseline 2. Psoriasis (any type and location) 3. Atopic dermatitis 4. Facial acne and rosacea 5. Dermatophytic skin infections 6. Parkinson’s disease 7. Known immunosuppression ; HIV infection 8. Baseline severity score of scaling, erythema (inflammation) and/or itching of = 5 (severe) 9. Requiring continuous systemic or topical corticosteroid or antimycotic therapy 10. Continuous asthma inhalation treatment requiring > 800 mg corticosteroids 11. Not observing the following washout periods prior to study entry 12. Participation in any other investigational drug study in the 4 weeks before study entry 13. Planned treatment during the study period with drugs excluded per protocol 14. Severe diseases likely to interfere with the conduct / planned termination of the study (e.g. cancer, cardiac infarct, unstable angina pectoris) 15. Hypersensitivity to any ingredient of the study drugs 16. Uncontrolled diabetes 17. Suspected unreliability, poor co-operation or non-compliance 18. Inability to understand the nature, scope and consequences of the study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variables are the sum score of the symptoms of seborrheic dermatitis and as the investigator’s global assessment (IGA).
The sum score is derived as the sum of individual scores for scaling, erythema (inflammation), and itching/burning in facial target sites. Patients should present with at least 3 facial target sites preferably forehead/eyebrows; bridge of nose; nasolabial folds. The facial target are graded numerically for erythema, scales and itching/burning. The single symptoms are rated on a 6 point score from 0 to 5. The single scores are added to a total score (= sum score) for all randomized patients and an average, mean, score is then calculated from the total.
The investigator’s global assessment (IGA) is a coprimary variable. The IGA provides a subjective overall description/assessment of the acute disease status on a 6-point scale (static score).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as last visit of the last patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |